Massive Bio, a global precision oncology company, recently announced a partnership with FOMAT, the largest Embedded Research Organization (ERO) in the United States, to support AI-powered patient prescreening for oncology clinical trials. Launched in June 2026, the partnership supports patient prescreening across FOMAT’s community-based research network, currently running a pilot project to test the efficiency of the integrated workflow before expanding its scope.
Despite significant advances in oncology research, the majority of cancer patients who could benefit from clinical trials never enroll, often because the connection between patients and available studies is fragmented, delayed, or simply never made. Prescreening, the process of identifying whether a patient may be eligible for a trial before committing to a full eligibility review, is one of the most critical and time-sensitive steps in that journey. When done well, it reduces burden on both patients and sites while accelerating the path to enrollment.
Through this partnership, Massive Bio’s AI platform will be applied within FOMAT’s physician network to analyze patient profiles and identify potential clinical trial eligibility across oncology indications. Patients identified through the prescreening process will be guided toward matched trials, reducing the time between diagnosis and access to potentially life-extending research options. The pilot is designed to test the efficiency and scalability of this integrated workflow before a broader rollout of the collaboration.
FOMAT, headquartered in Oxnard, California, recently became the largest ERO in the United States following its acquisition of Topography Health’s research site business unit in May 2026. The company now operates a network of 40+ investigator sites across six states, Maryland, California, Colorado, New Mexico, Michigan, and North Carolina, embedding clinical research directly into standard-of-care settings. FOMAT’s model prioritizes diverse and underserved patient populations, with 91% of recruitment driven through its community partner network. The partnership with Massive Bio extends FOMAT’s capabilities by layering AI-driven prescreening onto its existing infrastructure, strengthening the pipeline from patient identification to trial enrollment.
“Connecting cancer patients to the right clinical trials at the right time is at the heart of what we do,” said Selin Kurnaz, Co-Founder and CEO of Massive Bio. “FOMAT has built something remarkable, a trusted research network that reaches patients where they already receive their care. By bringing our AI prescreening capability into that environment, we can identify eligible patients earlier and reduce the friction that too often stands between a patient and a trial that could change their outcome.”
“From a clinical standpoint, the earlier we can identify a patient’s potential trial eligibility, the more options we can put in front of them,” said Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical AI Officer of Massive Bio. “Prescreening has historically been manual, slow, and inconsistent. Embedding AI into FOMAT’s community-based sites means we can bring speed and precision to that step without disrupting the physician relationships that make FOMAT’s model work. For patients in communities that have long been underrepresented in clinical research, this kind of infrastructure matters enormously.”
“This partnership reflects the kind of strategic collaboration we are actively building across the clinical trial ecosystem,” said Toygun Rauf Onaran, SVP of U.S. Provider Engagement and Partnerships at Massive Bio. “FOMAT is the largest embedded research organization in the country, and their footprint in community-based oncology is exactly where our prescreening technology creates the most value. We are starting with a focused pilot, but the potential to scale this across FOMAT’s full network represents a meaningful expansion of how many patients we can ultimately reach.”
“Clinical research can only transform lives if patients have a clear path to access it. This pilot brings together Massive Bio’s innovative AI technology and FOMAT’s embedded research model to identify trial opportunities earlier and within the healthcare settings patients already know and trust. We’re excited to evaluate how this approach can accelerate access and, if successful, expand Oncology research opportunities for more communities across our growing national footprint,” said Nicholas Focil, CEO of FOMAT.
Massive Bio serves patients across 17 markets and has facilitated more than 19,000 clinical trial matches to date. The company’s AI platform is backed by a peer-reviewed prospective study published in ESMO Real World Data and Digital Oncology, demonstrating four times faster trial matching with measurable accuracy across 3,804 real-world cancer patients. Massive Bio is a recipient of the DiMe Seal from the Digital Medicine Society and is listed in the CMS Medicare App Library, connecting its platform to more than 68 million Medicare beneficiaries.
The prescreening project is currently in its pilot phase, with both organizations evaluating outcomes and patient reach before determining the timeline and scope of a broader expansion.
For similar news on Cancer, please read:
1) Massive Bio and CureMatch Partner to provide AI powered cancer treatment
2) Verily and OneOncology collaborate to advance cancer research
3) IDEXX Laboratories Now Offers Cancer Testing Features for Dogs in the UK
